CodeBreak 200 is a global, randomized, open-label phase III trial aiming to assess the activity of sotorasib versus docetaxel in the second line for patients with advanced KRAS-mutated NSCLC. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.